Literature DB >> 1888102

Physiological modelling of organic compounds.

M E Andersen1.   

Abstract

In pharmacokinetic modelling the body is represented as a set of compartments. The characteristics of these compartments are defined either by fitting predetermined mathematical equations to the data ('data-based compartments') or by defining compartments based on the actual biological structure of the animal ('physiologically based compartments'). Physiological models of chemical disposition are developed using these physiologically based compartments. These models then consist of sets of organs or types of tissue compartments whose characteristics are based as far as possible on the anatomy and physiology of the test species. Individual organs or types of tissue are defined with respect to their blood flow, volume, kinetic constants for metabolism, storage capacity for the compound involved, protein binding and other relevant characteristics. Linking these compartments together in a proper anatomical arrangement yields the physiological model for compound disposition. This paper provides an overview of the basics for constructing physiological models for organic compounds, focusing on the structure of individual compartments in these models and the data required for model development. Some past applications of physiological models are reviewed and speculation offered on future developments in this field.

Mesh:

Year:  1991        PMID: 1888102     DOI: 10.1093/annhyg/35.3.309

Source DB:  PubMed          Journal:  Ann Occup Hyg        ISSN: 0003-4878


  8 in total

Review 1.  Whole body pharmacokinetic models.

Authors:  Ivan Nestorov
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Reactivity parameters in structure-activity relationship-based risk assessment of chemicals.

Authors:  J D McKinney
Journal:  Environ Health Perspect       Date:  1996-08       Impact factor: 9.031

Review 3.  A proposed approach to study the toxicology of complex mixtures of petroleum products: the integrated use of QSAR, lumping analysis and PBPK/PD modeling.

Authors:  H J Verhaar; J R Morroni; K F Reardon; S M Hays; D P Gaver; R L Carpenter; R S Yang
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

Review 4.  Applications of physiologic pharmacokinetic modeling in carcinogenic risk assessment.

Authors:  D Krewski; J R Withey; L F Ku; M E Andersen
Journal:  Environ Health Perspect       Date:  1994-12       Impact factor: 9.031

Review 5.  Physiologically based pharmacokinetic analyses of simple mixtures.

Authors:  K Krishnan; H J Clewell; M E Andersen
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

Review 6.  Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.

Authors:  D C Dorman; S L Allen; J Z Byczkowski; L Claudio; J E Fisher; J W Fisher; G J Harry; A A Li; S L Makris; S Padilla; L G Sultatos; B E Mileson
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

Review 7.  Application of Gut Cell Models for Toxicological and Bioactivity Studies of Functional and Novel Foods.

Authors:  Martin Trapecar; Avrelija Cencic
Journal:  Foods       Date:  2012-12-13

8.  A phased approach for assessing combined effects from multiple stressors.

Authors:  Charles A Menzie; Margaret M MacDonell; Moiz Mumtaz
Journal:  Environ Health Perspect       Date:  2007-01-24       Impact factor: 9.031

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.